文献速递乳腺癌

新辅助化疗后淋巴结降期省略腋窝淋巴结清扫的肿瘤学结局

Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy.
PubMed 文献 · JAMA Oncol · 2024-01-01

这项在11国25中心开展的多中心回顾性队列研究纳入1144例新辅助化疗后淋巴结转阴的Ⅱ-Ⅲ期乳腺癌患者,评估省略腋窝淋巴结清扫后行前哨淋巴结活检或靶向腋窝清扫的肿瘤学结局。全队列5年腋窝复发率1.0%,靶向腋窝清扫与前哨淋巴结活检的3年腋窝复发累积发生率无显著差异(0.5% vs 0.8%,P=0.55)。结果支持在该人群中省略腋窝淋巴结清扫。

要点

  • 新辅助化疗后淋巴结转阴患者省略腋窝淋巴结清扫,5年腋窝复发率仅1.0%。
  • 靶向腋窝清扫组与前哨淋巴结活检组3年腋窝复发率无显著差异(0.5% vs 0.8%,P=0.55)。
  • 靶向腋窝清扫组夹标淋巴结成功取出率97%,前哨淋巴结活检组(未定位)为86%。

核心结论

  • 该队列研究显示,在新辅助化疗后淋巴结转阴的乳腺癌患者中腋窝复发罕见,靶向腋窝清扫相比前哨淋巴结活检未显著降低复发,结果支持在该人群中省略腋窝淋巴结清扫。

研究设计与样本

  • 多中心回顾性队列研究,在11个国家的25个中心开展,2013年4月至2020年12月连续纳入1144例经活检证实的Ⅱ-Ⅲ期淋巴结阳性乳腺癌患者。
  • 暴露为前哨淋巴结活检或靶向腋窝清扫后省略腋窝淋巴结清扫;采用竞争风险分析计算腋窝、局部区域及任何侵袭性复发的累积发生率。

主要发现

  • 全队列5年任何腋窝复发率为1.0%(95%CI 0.49%-2.0%),局部区域复发率为2.7%(95%CI 1.6%-4.1%),任何侵袭性复发率为10%(95%CI 8.3%-13%)。
  • 靶向腋窝清扫组与前哨淋巴结活检组的3年腋窝复发累积发生率无显著差异(0.5% vs 0.8%,P=0.55)。
  • 靶向腋窝清扫组夹标淋巴结成功取出率为97%,前哨淋巴结活检组(未定位)为86%。
  • 靶向腋窝清扫组与前哨淋巴结活检组平均(SD)前哨淋巴结检出数分别为3(2)枚与4(2)枚(P<.001),平均(SD)切除淋巴结总数分别为3.95(1.97)枚与4.44(2.04)枚(P<.001)。
  • 靶向腋窝清扫组接受淋巴结放疗的比例高于前哨淋巴结活检组(85% vs 78%,P=.01)。

临床怎么用

  • 原文结论认为,该结果支持在新辅助化疗后淋巴结转阴的乳腺癌患者中省略腋窝淋巴结清扫。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Data on oncological outcomes after omission of axillary lymph node dissection (ALND) in patients with breast cancer that downstages from node positive to negative with neoadjuvant chemotherapy are sparse. Additionally, the best axillary surgical staging technique in this scenario is unknown. OBJECTIVE: To investigate oncological outcomes after sentinel lymph node biopsy (SLNB) with dual-tracer mapping or targeted axillary dissection (TAD), which combines SLNB with localization and retrieval of the clipped lymph node. DESIGN, SETTING, AND PARTICIPANTS: In this multicenter retrospective cohort study that was conducted at 25 centers in 11 countries, 1144 patients with consecutive stage II to III biopsy-proven node-positive breast cancer were included between April 2013 and December 2020. The cumulative incidence rates of axillary, locoregional, and any invasive (locoregional or distant) recurrence were determined by competing risk analysis. EXPOSURE: Omission of ALND after SLNB or TAD. MAIN OUTCOMES AND MEASURES: The primary end points were the 3-year and 5-year rates of any axillary recurrence. Secondary end points included locoregional recurrence, any invasive (locoregional and distant) recurrence, and the number of lymph nodes removed. RESULTS: A total of 1144 patients (median [IQR] age, 50 [41-59] years; 78 [6.8%] Asian, 105 [9.2%] Black, 102 [8.9%] Hispanic, and 816 [71.0%] White individuals; 666 SLNB [58.2%] and 478 TAD [41.8%]) were included. A total of 1060 patients (93%) had N1 disease, 619 (54%) had ERBB2 (formerly HER2)-positive illness, and 758 (66%) had a breast pathologic complete response. TAD patients were more likely to receive nodal radiation therapy (85% vs 78%; P = .01). The clipped node was successfully retrieved in 97% of TAD cases and 86% of SLNB cases (without localization). The mean (SD) number of sentinel lymph nodes retrieved was 3 (2) vs 4 (2) (P < .001), and the mean (SD) number of total lymph nodes removed was 3.95 (1.97) vs 4.44 (2.04) (P < .001) in the TAD and SLNB groups, respectively. The 5-year rates of any axillary, locoregional, and any invasive recurrence in the entire cohort were 1.0% (95% CI, 0.49%-2.0%), 2.7% (95% CI, 1.6%-4.1%), and 10% (95% CI, 8.3%-13%), respectively. The 3-year cumulative incidence of axillary recurrence did not differ between TAD and SLNB (0.5% vs 0.8%; P = .55). CONCLUSIONS AND RELEVANCE: The results of this cohort study showed that axillary recurrence was rare in this setting and was not significantly lower after TAD vs SLNB. These results support omission of ALND in this population.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Montagna G, Mrdutt MM, Sun SX, et al. Omission of Axillary Dissection Following Nodal Downstaging With Neoadjuvant Chemotherapy. JAMA Oncol. 2024. PMID: 38662396. doi:10.1001/jamaoncol.2024.0578

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。